Vancouver, British Columbia--(Newsfile Corp. - June 21, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biopsychedelics company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders, today announced an exclusive agreement with Clearway Global LLC ("Clearway").
Philip Young, CEO of Lobe stated, "We are pleased to have the opportunity to team up with the Clearway network and in particular with Dr. Fred Sancilio, a global expert in drug development and strategic planning. Dr. Sancilio brings over 40 years of pharmaceutical experience to our program and has a track record of success that is unmatched".
Dr. Fred D. Sancilio, Founder and CEO of Clearway commented "We are excited to be part of this evolving new area of pharmaceutical research that is demonstrating incredible potential to treat brain disorders that were previously believed to be untreatable. Biopsychedelics, such as those being developed at Lobe, present entirely new mechanisms of action that may change the way we treat post-traumatic stress disorder (PTSD) and other neurologic diseases. Mental illness is a wide-open field of research, and I am optimistic that Lobe is on the right path toward helping patients who suffer from these diseases".
In recent preclinical studies, treatment with Lobe's unique platform technology combining N-acetyl cysteine (NAC) with the bio psychedelic psilocybin, showed statistically significant positive results in a model of PTSD when compared to either moiety alone. In association with Clearway the Company plans to develop proprietary new chemical entities (NCEs) that improve upon naturally derived psychedelic molecules which can be unstable as pharmaceutical drugs. These NCEs are being studied as potentially low dose therapeutics without the psychedelic effect to allow patients to be treated at home or by their family physician.
Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.
Clearway Global, LLC, a wholly owned subsidiary of Sancilio & Company, provides early and mid-stage biopharmaceutical companies a world class network of development partners including international experts in regulatory affairs, business development, pre-clinical & clinical development, formulations, analytical chemistry, manufacturing, and controls. Clearway's founder, Dr. Fred Sancilio, MS, PHD is a recognized leader in drug development, analytical chemistry, corporate strategy and regulatory affairs. He is a serial entrepreneur and has contributed to dozens of successful start-ups that are now industry leaders.
For further information please contact:
Lobe Sciences Ltd. Philip J Young, CEO info@lobesciences.com Tel: (949) 505-5623
NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
This does not constitute an offer to sell or a solicitation of offers to buy any securities.
Disclaimer for Forward Looking Statements
This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company's drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company's corporate goals and objectives; and other risk factors detailed in the Company's continuous disclosure filings from time to time, as available under the Company's profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/128433
As we move toward the end of Q2, it’s time to start thinking about earnings. Looking back at the quarter, analysts are predicting earnings growth of 8%, which may rise to 11% heading into next year. It’s a rosy picture, but it’s also not a sure thing. GDP contracted in Q1, by nearly 1.5%, and some estimates are showing 0% growth in Q2. Such results would meet the technical definition of a recession – and recession is hardly the usual environment to find robust earnings growth. Looking at current
The number of companies stepping up to cover travel costs for U.S. employees seeking abortion services is growing following a decision by the U.S. Supreme Court on Friday to overturn its landmark Roe v. Wade.
(Bloomberg) -- Robinhood Markets Inc. faced a more dire situation during the height of last year’s meme-stock frenzy than executives at the online brokerage let on publicly, according to a report from top Democrats on a key congressional committee. Most Read from BloombergSupreme Court Overturns Roe, Transforming Abortion-Rights FightStocks Roar Back With Best Week in a Month: Markets WrapJuul’s Vaping Products Are Ordered Off the Market in the USJustice Kavanaugh Says States May Not Bar Travel
Nuclear submarine supplier to be sold to US buyer after diplomatic row Russian default expected within days Retail sales volumes down 0.5pc in May FTSE 100 rises strongly Ambrose Evans-Pritchard: The pro-Brussels establishment is painting Brexit as an economic disaster to reverse it Sign up here for our daily business briefing newsletter
Tesla plant near Shanghai is going to shut down temporarily, according to reports. On Wednesday, Reuters reported that Tesla (ticker: TSLA) will shut down production in China for a couple of weeks at the start of July to upgrade equipment. Tesla didn’t return a request for comment.
Shares of the specialty pharmaceutical company Bausch Health Companies (NYSE: BHC) are surging today in response to the news that Joseph Papa has resigned from the board of directors effective immediately. Over the past six years, Papa has been instrumental in lowering the company's sky-high debt and keeping it out of bankruptcy court. Bausch said in a statement Thursday evening that billionaire hedge fund manager John Paulson will fill the vacant board position.
“Time is running out for cash-burning companies kept afloat with easy access to capital,” New Constructs CEO David Trainer said in a Thursday research note.
Earlier this month, the S&P 500 officially entered a bear market; its current year-to-date loss stands at 21%, and the NASDAQ, which has fallen faster and farther, stands at a 30% ytd loss. The rapid reversal not only put the bulls back in the corral, but also erased all of last year’s stock market gains, leading most analysts to start meditating on the prospects of recession. Among the headwinds they’re considering are the highest rates of inflation in over 40 years and in response, a sharp tur
High-yield dividend stocks are a major component of my stock portfolio. Here are three income stocks that have room for solid gains in the next year and even better gains over the long run. The blue-chip business development company (BDC) Main Street Capital (NYSE: MAIN) has held up better than the S&P 500 index, which is down 21% so far this year.
Energy prices are high. But bargain-hunter Buffett continues to bet on big oil.
Dividend stocks are the new darlings in S&P 500. But investors are getting burned on those stocks, too.
The merger of the special-purpose acquisition company Gores Guggenheim and the electric-vehicle company coming from Volvo is done.
Bitcoin bear markets aren't unusual. But cryptocurrencies have never faced such an aggressive Federal Reserve. Welcome to the crypto ice age.
The drop is exciting some Berkshire investors because the stock now trades for 1.3 times Barron's estimate of its June 30 book value, compared with more than 1.5 times at its March high.
Shares in Polestar Automotive Holding UK PLC jumped 16% on their first day of trading Friday, after the Swedish electric-vehicle maker completed a merger with a special-purpose acquisition company amid plans to expand globally. Polestar agreed to be acquired by blank-check company Gores Guggenheim in September. The auto maker is a unit of Volvo Car AB, which in turn is owned by Zhejiang Geely Holding Group Co. of China.
In this article, we will look at 10 stocks to profit from inflation. If you want to explore similar stocks, you can also read 5 Stocks to Profit from Inflation. Billionaire investor and hedge fund manager of the world’s largest hedge fund, Bridgewater Associates, Ray Dalio shared his views on the current economic situation that […]
U.S. stock indexes moved more than 2% higher, as investors shifted their views about central bank policy after weak economic data.
Shares in the biggest U.S. banks rallied on Friday after they passed the Federal Reserve's annual health check, but Bank of America underperformed with test results implying it needs a larger-than-expected capital buffer, which could limit share buybacks and dividends. While the broader equity market also rallied on Friday, Wells Fargo & Co, up 7.5%, was the biggest gainer among the 34 lenders that underwent the Fed's so-called stress test, which measures how they would fare in a hypothetical severe economic downturn. The group would have roughly twice the capital required under Fed rules in the downturn scenario, it said.
High inflation could be here to stay. Make the necessary adjustments.
Shares of Meta Platforms (NASDAQ: META), the parent company of Facebook, were rising quickly today on seemingly no company-specific news. Instead, a rebound in the tech sector appears to be sending Meta's stock higher today. The tech stock had gained 5.8% as of 1:22 p.m. ET on Friday.